ADHD (attention deficit hyperactivity
disorder) is a chronic condition, affecting in the childhood & continued in
the adulthood if not treated well in time. Symptoms of ADHD include a
combination of tenacious problems, like impulsive behavior difficulty sustaining
attention, and hyperactivity etc.
Although the exact risk factor of ADHD is
not clear, some environmental risk factors such as premature birth &
prenatal tobacco exposure and genetics are considered as serious risk factors,
leading to the occurrence of ADHD. Similarly, while there is no breakthrough
for ADHD, early detection & treatment can help patients to manage their
symptoms.
There are several options available in the
market relating to the detection, treatment & therapeutics of ADHD, ranging
from behavioral intervention to prescription medication. Moreover, antibiotics and other therapeutics
developed with the advent technology intervention are providing good outcomes,
easing the conditions to an extent. Hence, the global ADHD Therapeutics Market has become a well-established
& pervasively growing market.
Acknowledging the value this market is
garnering currently and the growth prospect the market is demonstrating
worldwide, Market Research Future (MRFR), recently published a brilliant study
report giving out the complete market prognosis up till 2024. According to
MRFR, the Global ADHD Therapeutics market is expected to grow exponentially,
registering a phenomenal CAGR during the forecasted period.
Other factors propelling the market growth
include increasing risk factors, proliferating healthcare sector along with the
increasing number of advanced HC facilities and the increasing awareness about
the treatment method. Improving economic conditions that enable access to the
quality life & to the improved healthcare worldwide are providing impetus
to the market growth.
Technological advancements transpired in
the medical science backed by the substantial investments in the R&D
activities for the innovation & development of novel treatments &
medicines, foster the market growth of ADHD Therapeutics, excellently.
On the other hand, factors such as
incidents of drug resistance, and unmet clinical needs, coupled with the high
cost associated with the treatments are expected to restrict the market growth.
Nevertheless, the emergence of Biosimilars would certainly avail affordable,
cost- effective medical products, which will in turn, propel the market growth
of ADHD Therapeutics.
Global ADHD Therapeutics Market Competitive
Analysis
The global ADHD Therapeutics market is a
fragmented market with a large number of players. Product development strategy
has been curtailed by the excellent efficiency and efficacy of drugs. However,
the rise of drug resistance has opened doors for new drug development and is an
opportunity for a new market leader. The rise of spurious and counterfeit
medicines have reduced the total market revenues and at the same time displaced
standard drugs off the market. Key Players are focusing on innovative products
with minimum adverse effects, as well as targeting emerging applications to
leverage growth opportunities.
Industry/Innovations/Related News:
December 04, 2017 – Akili Interactive Labs
(US) launched a video game designed to treat kids with ADHD. Although the FDA
approval for the game is still awaited, Akili's ADHD videogame is the world’s
first prescription video game & closest to commercialization. The company
is also working on a range of games and digital medicines designed to medically
treat cognitive conditions such as depression and dementia.
Global ADHD Therapeutics Market
Segmentation
Global ADHD Therapeutics Market is
segmented into 3 key dynamics for the convenience of the report and enhanced
understanding;
By Drug Types : Comprises Stimulants
and Non-stimulants
By Distribution Channels : Clinics, Hospitals, Pharmacies, and
Research Laboratories among others.
By Regions : North America,
Europe, APAC and Rest of the World.
Global ADHD Therapeutics Market Regional
Analysis
Geographically, North America accounts for
the leading market for ADHD Therapeutics with the largest market share, followed
by the markets of Europe & Asia Pacific, respectively. The market is
growing due to the largest contribution from the significantly growing market
of the US. attributing to the high expenditure on the health care. Continuing
with the same growth trends, the North America market is likely to retain its
dominance during the review period.
Key Players :
The ADHD Therapeutics Market players include Advanz Pharmaceutical (Canada), Eli
Lilly and Company (US), Highland Therapeutics Inc. (Canada), Janssen
Pharmaceuticals, Inc. (Belgium), NEOS Therapeutics, Inc. (US), Pfizer Inc.
(US), Novartis AG (Switzerland), Noven Pharmaceuticals, Inc. (US), Shire (US),
Teva Pharmaceutical Industries Ltd. (Israel), Impax Laboratories, LLC (US),
GlaxoSmithKline plc (UK) and Purdue Pharma L.P. (US)
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street, 5Th Floor,
New
York, New York 10013
United
States of America
+1 628
258 0071
Email:
sales@marketresearchfuture.com
0 Comments